Clinical Trials Browser

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02328014 2025-12-09

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Phase 1/2 Completed

40 enrolled 12 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

113 enrolled 19 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT04257578 2025-10-08

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

Phase 1/2 Active not recruiting

23 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

Phase 1/2 Terminated

60 enrolled 20 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04630756 2025-04-09

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Phase 1/2 Completed

40 enrolled 31 charts

Advanced Haematological Malignancies

NCT04419389 2025-03-17

R/R

Phase 1/2 Terminated

1 enrolled 4 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03571308 2023-09-28

ACCEPT

Phase 1/2 Completed

39 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT04502394 2022-08-04

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Phase 1/2 Unknown

84 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04961801 2022-03-08

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Phase 1/2 Terminated

25 enrolled 11 charts

Lymphoid

DLBCL

Clinical Trials

Soundtrack-E

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Avo In R/R And Previously Untreated MCL

Mosunetuzumab for CLL MRD Clearance

KEYNOTE145

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

A Study Of The Selective PKC-β Inhibitor MS- 553

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

R/R

ACCEPT

ARIA

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies